Predictive Oncology Receives Nasdaq Notice for Minimum Bid Price Noncompliance
Predictive Oncology receives Nasdaq notice due to minimum bid price noncompliance, highlighting challenges in stock valuation. #PredictiveOncology #NasdaqCompliance
Executive Summary
Predictive Oncology Inc. (Predictive Oncology), a biotechnology company specializing in AI-driven cancer research and drug discovery, has received a notice from Nasdaq regarding noncompliance with the minimum bid price requirement. This notice signals that the company’s stock price has fallen below Nasdaq’s $1.00 minimum bid price threshold, triggering a compliance review process.
Company Overview
Founded in 2013 and headquartered in New York, Predictive Oncology leverages artificial intelligence and machine learning to develop personalized cancer therapies and accelerate drug development. The company’s proprietary platforms integrate biological data with computational models to identify effective treatment options.
Details of Nasdaq Notice
On June 30, 2025, Nasdaq issued a notification to Predictive Oncology indicating that the company’s closing bid price had been below $1.00 for 30 consecutive business days, which is below the minimum requirement for continued listing. The company has 180 calendar days to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
Recent Stock Performance (2023-2025)
| Date | Closing Price (USD) | Volume (Shares) |
|---|---|---|
| June 1, 2023 | 1.25 | 150,000 |
| December 1, 2023 | 1.10 | 120,000 |
| June 1, 2024 | 0.95 | 180,000 |
| June 30, 2025 | 0.85 | 200,000 |
Strategic Implications
The Nasdaq notice presents a critical challenge for Predictive Oncology, as failure to regain compliance could result in delisting, adversely affecting liquidity, investor confidence, and access to capital markets. The company may consider strategic initiatives such as reverse stock splits, enhanced investor relations efforts, or operational improvements to boost stock price.
Risks and Considerations
- Potential delisting from Nasdaq if compliance is not restored.
- Negative market perception impacting fundraising and partnerships.
- Volatility in stock price due to market and operational factors.
Conclusion
Predictive Oncology’s receipt of a Nasdaq minimum bid price noncompliance notice underscores the importance of addressing stock valuation challenges promptly. Stakeholders should monitor the company’s corrective actions and market developments closely.